GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NFL Biosciences SA (XPAR:ALNFL) » Definitions » Net Income From Continuing Operations

NFL Biosciences (XPAR:ALNFL) Net Income From Continuing Operations : €-3.75 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NFL Biosciences Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. NFL Biosciences's net income from continuing operations for the six months ended in Dec. 2023 was €-1.64 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was €-3.75 Mil.

NFL Biosciences Net Income From Continuing Operations Historical Data

The historical data trend for NFL Biosciences's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NFL Biosciences Net Income From Continuing Operations Chart

NFL Biosciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial -0.27 -0.26 -0.98 -2.44 -3.75

NFL Biosciences Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial - -1.07 -1.37 -2.11 -1.64

NFL Biosciences Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-3.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NFL Biosciences (XPAR:ALNFL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NFL Biosciences SA (XPAR:ALNFL) » Definitions » Net Income From Continuing Operations
Comparable Companies
XPAR:ALTHX XPAR:ALPAT XPAR:ALHYG XPAR:ALINT XPAR:FALG XPAR:POXEL XPAR:ALVET XPAR:ALBPS XPAR:ALMDP XPAR:ALQGC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
82F:Germany
Address
199 rue Helene Boucher, Castelnau-le-Lez, FRA, 34170
Website
https://www.nflbiosciences.com/
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.

NFL Biosciences (XPAR:ALNFL) Headlines

No Headlines